Metabolic and epigenetic dysregulation in IDH1/2-mutant gliomas: A microglial-mediated mechanism of blood-brain barrier disruption
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.115970 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Xuan-Hao Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China; Jilin Province Neuro-oncology Engineering…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Blood-Brain Barrier, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jilin Provincial Science and Technology Department, Jilin Province Development and Reform Commission, Jilin Provincial Scientific and Technological Development Program.
Abstract (Originalsprache)
Gliomas are a group of highly invasive and recurrent tumors originating from neural stem cells or glial progenitor cells. According to data from the Central Brain Tumor Registry of the United States published in 2023, the global incidence of gliomas is estimated at approximately 2.53 per 100,000 individuals(Ostrom et al., 2023[1]). Although surgical resection remains the primary treatment strategy, the 2021 WHO Classification of Tumors of the Central Nervous System reports that the five-year survival rate for gliomas typically ranges from 80 % to 90 %, whereas low-grade gliomas with IDH-wildtype mutations have a five-year survival rate of approximately 50 % to 60 %(Louis et al., 2021[2]). Therefore, IDH1/2 mutations are widely considered favorable prognostic markers in gliomas. However, recent studies have indicated that, compared to IDH-wildtype gliomas, IDH1/2-mutant gliomas often exhibit a significant reduction in survival time and a marked deterioration in prognosis following progression or recurrence. This suggests that, even for molecular subtypes with initially favorable prognoses, progression to a higher-grade state, their biological behavior may rapidly shift toward that of more aggressive gliomas, and may be accompanied by varying degrees of blood-brain barrier (BBB) disruption. This review aims to comprehensively examine the association between IDH1/2 mutations and BBB disruption, elucidating how IDH1/2-mutant gliomas alter tumor-associated metabolic and epigenetic pathways, which subsequently influence microglial activation and polarization, contributing to BBB impairment. Furthermore, we propose that microglia-mediated BBB disruption may be one of the underlying mechanisms contributing to complications in IDH1/2-mutant gliomas, such as vasogenic edema and immune-mediated encephalopathy, both of which are closely associated with BBB breakdown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China; Jilin Province Neuro-oncology Engineering Laboratory, Changchun 130033, Jilin, China; Jilin Provincial Key Labo…
- Key Laboratory of Pathobiology, Department of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun 130012, Jilin, China.
Förderung
- Jilin Provincial Science and Technology Department
- Jilin Province Development and Reform Commission
- Jilin Provincial Scientific and Technological Development Program
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Pan, X. H., Lan, B. W., Wang, N., Su, J., & Gao, Y. F. (2026). Metabolic and epigenetic dysregulation in IDH1/2-mutant gliomas: A microglial-mediated mechanism of blood-brain barrier disruption. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115970
Vancouver
Pan XH, Lan BW, Wang N, Su J, Gao YF. Metabolic and epigenetic dysregulation in IDH1/2-mutant gliomas: A microglial-mediated mechanism of blood-brain barrier disruption. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115970
BibTeX
@article{Pan2026,
author = {Pan, Xuan-Hao and Lan, Bei-Wu and Wang, Nan and Su, Jing and Gao, Yu-Fei},
title = {Metabolic and epigenetic dysregulation in IDH1/2-mutant gliomas: A microglial-mediated mechanism of blood-brain barrier disruption},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.115970}
}
EUVIMED